NEW YORK, Feb. 4 (GenomeWeb News) - Caprion Pharmaceuticals and Abbott Laboratories will collaborate on lung cancer antibody drug targets, the companies said today.
Abbott will evaluate a number of Caprion's cell surface drug targets for non-small-cell lung cancer, and plans to add additional targets from an ongoing Caprion project. In its research, Caprion has been applying its CellCarta proteomics approach, comparing plasma membrane proteins from normal and cancer tissue samples.
Abbott will obtain exclusive worldwide rights to develop selected targets and commercialize drugs that target them.
Under the agreement, Caprion will receive an upfront payment, milestone payments, and royalties from future product sales.